[{"Assets_0_Q3_USD":1784865000.0,"CommonStockSharesOutstanding_0_Q3_shares":303776032.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":368935000.0,"NetIncomeLoss_1_Q3_USD":97452000.0,"NetIncomeLoss_3_Q3_USD":252269000.0,"EarningsPerShareBasic_1_Q3_USD":0.32,"EarningsPerShareBasic_3_Q3_USD":0.84,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":303268000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":301999000.0,"Ticker":"EXEL","CIK":"939767","name":"EXELIXIS, INC.","OfficialName":"Exelixis Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7287350058.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20191030"}]